Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

By sjmartinez • April 2, 2025

Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko A, Yothers G, Tighiouart M, Ganz PA. Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial. JNCI Cancer Spectr. 2025 Apr 1:pkaf032. doi: 10.1093/jncics/pkaf032. Epub ahead of print. PMID: 40170372.

Tags: Cedars Sinai DoM, General Internal Medicine, Hematology/Oncology, Publications

The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies?

Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K, Nasseri Y, Murrell Z, Waters K, Mehta P, Zell JA, Hitchins MP, Gong[...]

Timing of Hypertensive Disorders of Pregnancy in Nulliparous Individuals and Risk of Incident Chronic Hypertension 2-7 Years Postpartum

Hauspurg A, Grobman W, Jancsura MK, Yee LM, Waks A, Simhan H, Levine LD, Theilen L, Greenland P, McNeil R, Bairey Merz CN, Shahrokni N,[...]

Response

Geft D, Matusov Y, Kolaitis N, DesJardin J, Barnett C, Hage A, De Marco T, Lewis MI. Response. Chest. 2026 Feb;169(2):e80-e81. doi: 10.1016/j.chest.2025.11.028. PMID: 41672669.